Flagship Pioneering Fund VI General Partner LLC insider trades: Generate Biomedicines (GENB) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Flagship Pioneering Fund VI General Partner LLC reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 2, 2026 | GENB | ↑ Buy | 1,562,500 | $16.00 | $25.0M | By Flagship Pioneering Fund VII, L.P. | Mar 2, 2026 (0d) |
| Mar 2, 2026 | GENB | ↑ Buy | 1,562,500 | $16.00 | $25.0M | By Pioneering Medicines 02, LLC | Mar 2, 2026 (0d) |
| Mar 2, 2026 | GENB | ↑ Buy | 1,562,500 | $16.00 | $25.0M | By FPN II, L.P. | Mar 2, 2026 (0d) |
| Aug 3, 2021 | OMGA | ↑ Buy | 1,176,469 | $17.00 | $20.0M | Indirect | Aug 5, 2021 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other GENB insiders
Open-market trades in the last 12 months
About Flagship Pioneering Fund VI General Partner LLC's insider trades
Flagship Pioneering Fund VI General Partner LLC is an insider at Generate Biomedicines (GENB). Since Aug 3, 2021, it has reported 4 open-market purchases worth $95.0M and no sales on SEC Form 4. In the last 12 months: 3 buys ($75.0M).
Its filings also include conversions (3 filings), other transactions (2 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GENB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.